Unlock Premium Data: Up to 50% Off InvestingProCLAIM SALE

Morgan Stanley sets $32.81 price target for RxSight with Overweight rating

EditorAmbhini Aishwarya
Published 12/05/2023, 02:09 AM
© Reuters.
RXST
-

NEW YORK - Morgan Stanley has recently initiated coverage on the medical device company RxSight (NASDAQ:RXST), assigning an Overweight recommendation and establishing a price target of $32.81. This target suggests a potential upside of 11.37% from the company's last closing price of $29.46.

Institutional investors have shown a strong belief in the prospects of RxSight, as evidenced by the latest data reflecting a significant uptick in institutional ownership. The number of funds holding RxSight shares has climbed by more than sixteen percent, totaling approximately 284 institutions. This surge in interest is further underscored by the growth in institutional shares held, which now exceed thirty million, marking a nineteen percent increase from the previous quarter.

The investment community's bullish stance is further supported by the current put/call ratio standing at a low 0.09, indicating that investors are more inclined to bet on RxSight's stock price rising rather than falling.

Among the key institutional players, Ra Capital Management has maintained its substantial holding of over three million RxSight shares. Artisan Partners (NYSE:APAM) has notably increased its investment by fourteen percent to nearly two-and-a-half million shares and has also significantly upped its portfolio allocation to the company. Similarly, Lord Abbett & Co has expanded its share count by twelve percent, reinforcing the trend of growing investor confidence in RxSight's market position and future performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.